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Abstract. Myosteatosis, the infiltration of fat in skeletal 
muscle, is associated with lower skeletal muscle density 
(SMD) as detected by computed tomography (CT). It increases 
with aging and obesity and is thought to play a role in the aeti-
ology of insulin resistance and type II diabetes. The clinical 
significance of myosteatosis in cancer cachexia, however, 
remains to be determined. Along with demonstrable subcu-
taneous and visceral lipolysis, myosteatosis may also be a key 
component of the syndrome. We aimed to investigate the use 
of human urine as a non-invasive way to screen for molecular 
biomarkers of myosteatosis/reduced SMD using SELDI-TOF 
mass spectrometry. Pre-operative CT scans of patients 
undergoing surgery for upper gastrointestinal or hepatopan-
creaticobiliary cancer were analysed at the level of the third 
lumbar vertebrae. Myosteatosis was inferred as the presence 
of reduced SMD, which was defined as Hounsfield units for 
skeletal muscle <39.5 (two standard deviations below a normal 
healthy cohort). Urine was analysed by mass spectrometry 
using CM10 and IMAC30 SELDI-chips. Peaks observed in 
the CM10 and IMAC30 chip types, showed marked expres-
sional differences between control and myosteatosis, were 
further investigated by mascot SELDI matrix matching. A 
total of 55 patients was recruited; 31 patients were found to be 
myosteatotic on CT scan. Application of the IMAC30-derived 
model to the entire cohort showed a sensitivity of 97%, speci-
ficity of 71% and an overall correctness of 85%. Application of 
the CM10 chipset-based model to the entire cohort, showed a 
77% sensitivity, 67% specificity and 73% overall correctness. 
Analysis of the peaks of interest resulted in the identification of 
significant fragments of cathepsin C, argin, arylsulfatase A and 
glial fibrillary acidic protein. We identified several potential 
urinary molecular biomarkers associated with reduced SMD 
in cancer. Such markers are potentially useful in deriving a 
clinical screening test for myosteatosis.
Introduction
Myosteatosis occurs in two forms: Fat deposition within 
myocytes (intramyocellular fat) and fat infiltration within the 
fascia between muscle layers (intermuscular fat) (1), although 
the latter is excluded by computed tomography (CT) scan 
analysis. Myosteatosis increases with aging and obesity, but it 
may also play a role in the development of human disease (1). 
The clinical significance of myosteatosis remains unclear but 
it appears to be involved in the aetiology of insulin resistance 
and type II diabetes mellitus through the modulation of both 
adipokine (e.g., adiponectin) secretion and nutritive muscle 
blood flow (2).
Cancer cachexia is a severe syndrome of skeletal muscle 
wasting and lipolysis that appears to develop as part of an 
aberrant host response to the presence of tumour (3). The 
clinical consequences of cachexia include increased rates of 
patient morbidity and mortality, and decreased rates of onco-
logic response to chemotherapy (4,5). Despite demonstrable 
subcutaneous and visceral lipolysis during cancer cachexia, 
myosteatosis and sequestration of fat into skeletal muscle may 
be a key component of the syndrome (6). Several pro‑inflam-
matory cytokines (e.g., IL-6 and TNF-α) and adipokines [e.g., 
zinc-α2-glycoprotein (ZAG) are involved in the aetiology of 
cancer cachexia] (7,8). In the past, members of our group have 
identified increased mRNA expression of ZAG a proposed 
lipid mobilising factor, in fat samples from cachectic cancer 
patients; however, serum ZAG levels were unchanged from 
controls (9). Visceral adipose tissue is lost more rapidly than 
subcutaneous adipose tissue during cachexia, suggesting 
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differential tissue-dependent responses to the wasting process. 
Recently, focus has concentrated on the concept of ‘fat-muscle 
crosstalk’ in cancer cachexia. Notably, the genetic ablation of 
lipolytic pathways in adipocytes protects against muscle mass 
loss in pre-clinical models of cancer cachexia (10). These data 
support the loss of visceral fat driven by lipolytic mechanisms 
as an early event in cancer cachexia with a potential effect on 
skeletal muscle.
We previously used cross-sectional magnetic resonance 
imaging (MRI) of quadriceps to demonstrate increased 
intermuscular fat in cancer patients compared with both 
elderly and young healthy controls (11). We also combined 
cross-sectional CT at the level of the third lumbar vertebra with 
ultra-structural analysis of rectus abdominis muscle biopsies 
by electron microscopy to demonstrate that intramyocellular 
lipid deposition is increased in cancer patients compared with 
controls (12). However, whether myosteatosis is a cause or 
effect of cancer cachexia remains to be elucidated. Certainly, 
insulin resistance is a key finding in previous clinical studies 
of cancer cachexia, with cancer patients demonstrating lower 
serum insulin and insulin: cortisol ratios, and higher serum 
glucose (13). Such insulin resistance represents one causative 
mechanism of skeletal muscle protein depletion in cancer 
cachexia through a lack of anabolic phosphatidylinositol 3 
kinase pathway signalling (13). Myosteatosis may play an even 
greater role in the development of cancer cachexia in those 
patients with obesity in the presence of skeletal muscle deple-
tion, so-called ‘sarcopenic obesity’. Previous cross-sectional 
CT studies showed that it is these individuals that have the 
worst overall prognosis from advanced lung and pancreatic 
cancer (14).
In an attempt to identify diagnostic biomarkers of 
cancer cachexia, we previously showed that MALDI-TOF 
mass spectrometric (MS) analysis can identify breakdown 
products of skeletal muscle protein in human urine (15). 
Furthermore, SELDI-TOF MS was capable of identifying 
diagnostic markers of upper gastrointestinal (uGI) cancer 
in the same substrate (16). Therefore, we hypothesised 
that a SELDI-TOF platform would also be used to identify 
protein/peptide biomarkers of myosteatosis in the urine of 
patients with cancer. The identity of such markers would 
not only offer insights into the development of myosteatosis, 
but also identify high-risk groups among individuals with 
cancer-associated weight loss.
Materials and methods
Materials. Buffers, gels and SELDI chips were from Bio-Rad 
(Hemel Hempstead, UK), and all other chemicals were 
obtained from Sigma‑Aldrich (Gillingham, UK) unless stated 
otherwise in the text.
Sample collection. Urine samples were obtained from uGI 
and hepatopancreaticobiliary (HPB) cancer patients who were 
undergoing potentially curative surgery approximately 4-6 
weeks after the cessation of chemotherapy. Urine samples were 
collected into a sterile container at induction of anaesthesia. 
They were snap frozen in liquid nitrogen and stored at ‑80˚C 
until use. The procedures were approved by the local research 
ethics committee. Written informed consent was obtained. 
The study conformed to the standards set by the Declaration 
of Helsinki.
Myosteatosis stratification. Skeletal muscle CSA was 
measured from routine CT scans performed prior to any 
surgical or oncological intervention. CT scans were recorded 
within an average of 23 days prior to supplying the urine 
samples. Digitally stored CT images completed with a spiral 
CT scanner for initial staging and routine diagnostic purposes 
were analysed using semi-automated software that permitted 
specific tissue demarcation using Hounsfield unit thresholds 
of -29 to +150 for skeletal muscles, -150 to -50 for visceral 
adipose tissue, and -190 to -30 for subcutaneous adipose tissue. 
Cross-sectional areas (cm2) were computed for each tissue by 
summing tissue pixels and multiplying by the pixel surface 
area. A transverse CT image from the third lumbar vertebrae 
(L3) was assessed for each scan date and tissue volumes esti-
mated. The muscles in the L3 region contain psoas, erector 
spinae, quadratus lumborum, transversus abdominus, external 
and internal oblique, and rectus abdominis. CT images were 
analysed by a single trained observer, tissue boundaries were 
manually corrected as needed. Cross-sectional area for muscle 
was normalized for stature (cm2/m2). Cut-off values for low 
muscularity were based on a CT-based sarcopenic obesity study 
of cancer patients (i.e., L3 skeletal muscle index: ≤38.5 cm2/m2 
for women and ≤52.4 cm2/m2 for men) (17) Myosteatosis was 
defined by the mean Hounsfield units for skeletal muscle, and 
values <39.5 (two standard deviations below a normal healthy 
cohort) were regarded as myosteatotic.
SELDI‑TOF‑MS. SELDI-chips (CM10 and IMAC30) were 
prepared for sample application according to the manufac-
turer's recommendations (16). IMAC30 chips were loaded 
with 0.1 M CuSO4 and washed with water. Chips were neutral-
ised with 0.1 M NaHAc (pH 4.0) and washed with water. A 
further 2 washes with 0.1 M NaHPO4 were completed. CM10 
chips and 0.5 M NaCl were washed twice with 0.1 M NaHPO4 
(pH 4.0). All chips were processed in a bioprocessor‑assembly 
by incubating 0.1 ml urine and 0.1 ml binding buffer 
[CM10: 0.1 M NaHPO4 (pH 4.0); IMAC30: 0.1 M NaHPO4, 
0.5 M NaCl] for 1 h at room temperature. Three washes were 
completed with 0.2 ml binding buffer for 5 min each at room 
temperature and 2 washes with 0.2 ml water. Samples were 
air dried and 2 times 1 ml energy absorbing matrix [sinapinic 
acid (SPA) in 50% CAN, 0.5% TFA] was added. Air-dried 
chips were analysed in PCS4000 SELDI-TOF instrument 
(Bio-Rad) by measuring the 1,000 to 25,000 Da range with 
a laser setting of 2.5 mJ. Spectra was exported as ‘.xml’ files. 
The SELDI instrument was calibrated using the ProteinCip 
All-In-one peptide standard (Bio-Rad). Source voltage was set 
as 25,000 V and detector voltage as 2,946 V. Quality control 
and consistency was ensured by using one random pool of 
urines on one spot per chip each. Spectral alignments of all 
quality controls ensured consistency of all spectra.
Data processing. ProteinChip Data Manager software 
(PCDMS) version 4.1 with integrated Biomarker Wizard cluster 
analysis (Bio-Rad) was used for analysis. SELDI-TOF-MS 
traces were split into two groups: Control and myosteatosis 
based on CT scan analysis. The baseline was subtracted from 
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individual m/z traces and profiles were normalised using total 
ion current, followed by identification of peak clusters using 
the cluster analysis tool. Peaks were selected in the first pass 
where the signal to noise (S/N) ratio was >5 and had a valley 
depth of at least 3. In the second pass the S/N ratio was 2 and 
the valley depth was also 2. The cluster mass window was set 
to 0.2% of mass. Clustered peaks were only included if they 
occurred in at least 10% of all spectra. The resulting P-values, 
ROC areas, mean and median m/z values, and intensities of 
the clustered peaks were exported and saved as ‘.csv’ files and 
used for model building. Heat‑maps using Pearson's correla-
tion and principle component analysis plots were calculated 
to assess global group divisions (i.e., myosteatosic and 
non-myosteatotic). A two-sample t-test was used to compare 
mean normalised intensities between the case and control 
groups. P<0.05 was considered statistically significant.
Model building and validation. Clustered peak lists were anal-
ysed with the Biomarker Pattern software (BPS; Bio-Rad). The 
m/z versus intensity matrices were analysed using decision 
tree-analysis, selecting the standard error rule of minimum 
cost-tree regardless of size. The method used was Gini. V-fold 
testing was set to 1,000. A total of 20 myosteatosis samples 
and 20 control samples were chosen randomly and used as the 
learning and testing dataset. The remaining 15 samples were 
used as the validation dataset for blind-testing. Sensitivity was 
defined as the probability of predicting myosteatosis cases, 
and the specificity was defined as the probability of predicting 
non-myosteatotic samples.
Peak isolation and identification. Peaks observed in the 
CM10 and IMAC30 chip-types which show marked expres-
sion differences between control and myosteatosis samples, or 
were branching points in the models were further investigated 
as detailed below: 0.5 ml of urine from positive or negative 
samples in relation to specific peaks was added to 30 ml CM10 
or IMAC30 spin column resins (Bio-Rad). A total of 0.75 ml 
of binding buffer [0.1 M NaHPO4 (pH 4.0) for CM10 resins 
and 0.1 M NaHPO4 (pH 7.0) and 0.5 M NaCl for IMAC30 
resins]was then added. These were incubated for 1 h at room 
temperature under constant agitation. Unbound material was 
removed and the resin was washed 4 times with 0.3 ml binding 
buffer. Bound material was separated by electrophoresis on a 
16.5% Tris-Tricine gel (Bio-Rad) and gel bands in the region 
of 2 to 10 kDa were excised after Coomassie staining (BioSafe 
Coomassie; Bio-Rad). Positive and negative samples were 
chosen on the presence or absence of a specific m/z peak to 
be identified based on SELDI‑TOF‑MS analysis. Proteins and 
peptides from gel bands were digested in situ with trypsin, 
the resulting peptides eluted with ACN, and analysed using 
LC-MS/MS as previously described (16). Fragmentation 
spectra were then processed by Xcalibur and BioWorks 
software (Thermo Fisher Scientific, Loughborough, UK) 
and submitted to the Mascot search engine (Matrix Science, 
London, UK) using UniProt/SwissProt (release July 2010, 
Homo sapiens, 18,055 sequences) as the reference database. 
Mascot search parameters were: Enzyme specificity trypsin, 
maximum missed cleavage 1, fixed modifications cysteine 
carbamidomethylation, variable modification methionine 
oxidation, precursor mass tolerance +/-3 Da, fragment ion 
mass tolerance +/-0.4 Da. Only Mascot hits with a false 
discovery rate of <0.05 were taken into consideration. 
Proteins with ≥2 peptide matches were analysed by pattern 
matching based on SELDI-TOF-MS measured expression 
levels of peaks of interest (expected abundance in selected 
samples) and observed presence of proteins. Peptide distri-
bution of identified peptides within a protein as well as 
calculated molecular mass of identified proteins was used to 
assess whether breakdown products were likely to account for 
mass variances between the expected mass and the molecular 
weight of the full-length protein.
Mascot‑SELDI matrix matching. Observed proteins with 
at least two peptide matches from the LC-MS/MS analysis 
were further analysed by pattern matching based on 
SELDI-TOF-MS measured expression levels of peaks of 
interest (expected abundance in selected samples). This was 
carried out using software written in-house, which compared 
observed protein expression patterns in a pre‑defined set of 
samples (LC-MS/MS results) against a matrix of peak patterns 
(SELDI-TOF clustered peak intensities, where estimated peaks 
are set to null) in the same set of samples. Scoring was based 
on sensitivity (percent observed over expected) and specificity 
(percent not observed over not expected). Results are presented 
in descending order of cumulative scores.
Results
Patient data. A total of 55 patients (mean age, 64 years) with 
uGI cancer was stratified according to the presence or absence 
of myosteatosis with 24 being regarded as non-myosteatotic 
(Table I). Data variables, with the exception of plasma CRP, had 
normal distributions. The non-myosteatotic control group was 
significantly shorter, lighter and older than the Myosteatotic 
group but had similar BMI and weight loss (Student's t-test) 
and similar CRP (Mann-Whitney U).
Four peak clusters in the IMAC30, and 8 in the CM10 
datasets showed statistically significant P‑values <0.05, which 
indicates a potentially significant difference in the expression 
levels for a particular protein or peptide cluster.
Decision tree analysis. Decision-tree modelling using the 
BPS of peak clusters of 20 random samples of each cohort 
was validated by the remainder of the entire cohort (4 control 
and 11 myosteatotic samples). Decision tree models are shown 
in Fig. 1A and D. The IMAC30 chipset-based model (Fig. 1A) 
showed a sensitivity of 100% and a specificity of 25% for 
the validation dataset, and application of the derived model 
to the entire cohort showed a sensitivity of 97%, and speci-
ficity of 71%. Application of the CM10 chipset‑based model 
(Fig. 1D) to the validation dataset gave a sensitivity of 73%, 
specificity of 25%, and for the entire cohort the values are 77% 
sensitivity, 67% specificity.
Statistical analysis of the m/z cluster peaks involved in the 
models and potential marker peaks showing low P-values are 
shown in Table II.
Of the 4 peak clusters in the IMAC30-based dataset which 
had either high model score values, or showed P-values <0.05, 
three were upregulated and one downregulated in myos-
teatosis (e.g., m/z 2,540 in Fig. 1B and m/z 4,373 in Fig. 1). 
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The CM10-based chipset showed 8 peak clusters of interest, 
of which one was upregulated, 6 downregulated and one 
unchanged in myosteatosis (e.g., m/z 2,544; Fig. 1E). All of 
these clustered peaks, which showed statistical significance 
from both the IMAC30 and CM10 dataset, were further inves-
tigated by enrichment of urinary proteins from 14 (IMAC30) 
and 22 (CM10) samples each, and excision of gel bands after 
electrophoresis and LC-MS/MS downstream processing, 
followed by Mascot searching and identification of proteins 
contained within the samples as described earlier (15). All 
lead m/z clusters have P-values <0.05.
Potential markers identified. All potential markers identified 
by Mascot-SELDI pattern matching are detailed in Table III.
Both the m/z 3,293 and 4,373 from the IMAC30 screen and 
m/z 3,905 from the CM10 chipset data could not be matched to 
observed expression patterns, and m/z 19,136 and 22,355 from 
the CM10 chipset were too far removed from the gel-analysed 
mass range to assign them to observed protein patterns. Both 
the m/z 2,540 and 4,022 clusters from the IMAC30 dataset 
matched Mannan-binding lectin serine protease 2 precursor 
(MASP2), and the m/z 2,540 peak also matched the expression 
pattern of gelsolin (GSN). The observed expression patterns 
of both agrin (AGRN) and dipeptidyl-peptidase 1, also known 
as cathepsin C (CTSC), matched the m/z 3,934 peak cluster. 
The downregulated m/z cluster at 2,544 matched to both aryl-
sulfatase A (ARSA) and glial fibrillary acidic protein (GFAP) 
expression profiles. The downregulated m/z 8,874 peak cluster 
expression profile matched Leucine-rich α-2-glycoprotein 
precursor (LRG1). The m/z 9,971 cluster was associated with 
cystatin‑B, and the observed histone H2AV (H2AFV) expres-
sion correlated with the m/z 7,271 peak. None of the peak 
clusters show any significant age‑or sex‑related expression 
differences.
The m/z distribution of individual peaks within a peak 
cluster shows the expected pattern of a heterogeneous popu-
lation of urinary molecular species. However, this does not 
exclude that some peak clusters may consist of more than one 
unique protein or peptide.
Discussion
In the present study, approximately 42% of patients with uGI 
cancer were found to have myosteatosis. One potential limita-
tion of this study is that no previously established definition 
of myosteatosis exists. A value of skeletal muscle density 
(SMD) 2 SD below the mean in a healthy population was used 
in a similar manner to definitions for sarcopenia and were 
selected from values stated in one small study (16). The popu-
lations described in other similar studies of skeletal muscle 
attenuation in healthy individuals are also small, however, 
and different (although similar) values could be obtained 
Table I. Demographics of the cohort (n=55).
Characteristics Non-myosteatotic, n=24 Myosteatosis, n=31 Entire cohort, n=55 
Mean age (years) 60 (10) 67 (7)a 64 (9)
Male:female  18:6 27:4 45:10
Height (cm2) 168.7 (8.4) 174.8 (7.3)a 172.1 (8.3)
Weight (kg) 72.7 (16.5) 82.9 (14.9)a 78.4 (16.3)
Weight loss (%) 6.7 (8.8) 5.3 (6.9) 5.9 (7.7)
BMI  25.5 (4.7) 27.2 (4.6) 26.4 (4.7)
CRP (mg/l)  13.5 (34.0) 12.5 (31.9) 12.9 (32.5)
Skeletal muscle mass  47.8 (9.9) 46.2 (7.6) 46.9 (8.6)
Mean HU  45.9 (4.6) 33.6 (4.6)a 39.0 (7.7)
Data is mean ± standard deviation or median (range) for C-reactive protein (CRP). aP<0.05, myosteatosis vs. non-myosteatosis (Student's t-test, 
Mann-Whitney U). BMI, body mass index.
Figure 1. Decision tree analysis models and expression profiles of potential 
biomarker peaks. Cluster-peaks implicated in the tree-analysis model using 
the IMAC30 chip-type (panel A) or the CM10 chip-type (D) stratifying 
myosteatosis (black) and control (grey) were plotted according to their nor-
malized intensity values (B and C and E, y-axis) for peak clusters of m/z 
2540 (B), 4373 (C) and 2544 (E).
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depending on the series chosen (18,19). Skeletal muscle attenu-
ation in the form of HU has recently been demonstrated to be 
associated with adverse outcome in patients with GI and lung 
cancer independent of BMI, skeletal muscle mass or weight 
loss (20). Values obtained for increased risk were <33 for 
individuals with BMI >25 or 41 for those with BMI <25 (20) 
and so are not dissimilar to the value of 39.5 chosen for all 
the participants as a cut-off value for this study. Using this 
definition, HU values were used to divide the cohort into two 
groups that had similar characteristics in terms of BMI, weight 
loss and CRP, suggesting that there was no difference between 
them in conventional measures of cachexia severity (21). The 
non-myosteatotic group were slightly older although the differ-
ence of seven years is unlikely to be clinically significant.
In this cohort, SELDI-TOF-MS was able to analyse 
and screen urine from uGI cancer patients for prospec-
tive myo steatosis biomarkers and to establish a proteomic 
fingerprint pattern which potentially can be used in clinical 
diagnostics. It was found that both IMAC30 and CM10 are 
useful chip-types for the analysis of human urine (16), and 
models based on the analysis of 55 samples were generated 
from cancer patients. The samples were measured on CM10 
and IMAC30 chips, and using the tree-analysis method, 
statistical models were established with overall sensitivities 
of 97% (IMAC30) and 77% (CM10) and specificities of 71% 
(IMAC30) and 67% (CM10) across the entire datasets. Using 
expression pattern matching, it was possible to assign several 
proteins identified in urine to the proposed biomarkers.
Cystatin-B is described as a protein that can stimulate 
cancer cell growth both in vitro and in vivo and recently 
has been shown to be a potential prognostic marker for lung 
cancer (22). However, this molecule has no direct known asso-
ciation with skeletal muscle wasting but has been shown to be 
associated with total fat mass, percentage body fat, abdominal 
fat and body fat distribution as measured by DEXA in a recent 
study examining cardiovascular risk factors in children (23).
MASP2 matched the m/z 2,540 and 4,022 clusters from 
the IMAC30 dataset; however, m/z 2,540 was shown to be 
downregulated, and m/z 4,022 upregulated. It is a possibility 
that this could be an indicator that fragmentation states are 
altered in myosteatosis by for example, lower quantities of 
other proteases, such as CTSC a lysosomal protease asso-
ciated with proteolysis after muscle trauma (24), which we 
found to be associated with the downregulated m/z 3,934 
cluster peak. It has been shown in previous studies to play a 
role in protein degradation and turnover particularly in the 
later stages of muscle wasting following disuse (25). Exercise 
injuries in mouse models have shown upregulation of CTSC 
in skeletal muscle (26), and our observed downregulation 
of the associated m/z cluster may indicate a dysfunction in 
muscle repair.
The downregulated m/z peak of 2,540 also matched the 
expression pattern of GSN, which is an actin‑filament modu-
lating protein and can be found in smooth and skeletal muscle 
cells, as well as a secreted form in plasma (27). Reported 
downregulation of GSN in breast cancer cells, ovarian carci-
nomas, and melanomas suggests that this molecule acts as a 
tumour suppressor (28). Underexpression of GSN has been 
shown to increase inflammation in MS and encephalitits. It 
has already been reported that recombinant human gelsolin 
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(rhp-GSN) can remit some inflammatory diseases in the 
animal model, such as burn injury, middle cerebral artery 
occlusion, and sepsis (29). The association of GSN and apop-
tosis has been deeply researched. Full-length GSN, and the 
C-terminal half of GSN are generally considered as having 
anti-apoptotic function (29).
AGRN, which also matched the same m/z cluster as CTSC. 
It is a component of the basal lamina on the surface of muscle 
fibres of the neuromuscular junction, and defects in this gene 
perturbs the maintenance of the neuromuscular junction (30), 
whereas an overexpression in a laminin‑deficient mouse model 
increases muscle integrity and regenerative capacity (31). The 
observed downregulation in the CM10-chipset based model 
could be related to a dysfunction of muscle regeneration. 
Conflicting with the downregulation observed herein, however, 
is the finding that the agrin fragment (CAF) has recently been 
identified as being elevated in the serum of a series of 73 older 
volunteers with sarcopenia compared with age matched 
controls (32). A decrease in CAF has also been associated with 
improvement of hand grip strength and muscle mass in patients 
who were undergoing rehabilitation for acute stroke (33). It is 
possible that this could reflect different mechanisms of wasting 
in aging and cancer whereby muscle regenerative ability is 
diminished in cancer but maintained in aging.
The downregulated m/z cluster at 2,544 matched to both 
ARSA and GFAP expression profiles. Mutations in ARSA 
can cause demyelination and GFAP is associated with central 
nervous system disorders (27) and chronic neuropathies (32).
The downregulated m/z 8,874 peak cluster expression 
profile matched LRG1, which is a secreted protein and has 
been postulated as a biomarker of ventricular dysfunction and 
heart failure (34). The reported upregulation associated with 
heart disease is in contrast with our observed downregulation 
of this marker, and its role in myosteatosis remains unclear. 
H2AFV expression correlated with the m/z 7,271 peak. Some 
members of the histone H1 family have been reported to 
be involved in cell survival in breast cancer cells and H1.2 
was identified as an apoptogenic factor (34). The measured 
SELDI-MS-based slight upregulation could be an indication 
of elevated apoptosis in general, and a specific role in muscle 
function, cancer or fat infiltration remains unclear.
With the exception of AGRN and CTSC, the poor asso-
ciations of some of these markers with known mechanisms of 
muscle wasting casts some doubt over the specificity of these 
results to changes in muscle quality in terms of intramyocel-
lular lipid. One possibility is that some of the markers listed 
above might also be associated with other factors, such as 
cancer type. The cohort here included patients with cancers of 
both oesophagogastric and pancreatic origin and the presence 
of unrecognised specific markers for these cancer types might 
skew any interpretation of the results  (35,36).
Additional potential limitations are that there may be 
effects on skeletal muscle HU other than intracellular lipid. 
A clear association between intramyocellular lipid and 
Hounsfield units has been demonstrated in healthy indi-
viduals (37) and also in patients with cancer cachexia. We 
have previously shown that the number and size of intramyo-
cellular lipid droplets is increased in the presence of cancer 
and increases further with weight loss/loss of adipose mass 
in other body compartments (12). Oedema has been shown to 
be an additional influence on mean Hounsfield unit of skeletal 
muscle in patients with cancer that would not be present in 
healthy volunteers (38). While a number of potential markers 
indicated such as CTSC, AGRN and arclsulfatase A may be 
associated with muscle or neuromuscular wasting several of 
these proteins are non‑specific or cancer specific. This may 
indicate that the models are describing both muscle wasting 
and additional factors, potentially including cancer progres-
sion or nutritional states unrecognised or not assessed in this 
cohort. The potential influence on mean Hounsfield units in 
patients with cancer by factors other than intramyocellular 
lipid also requires to be explored further.
In conclusion, stratification and pattern matching allowed 
us to search for specific myosteatosis-related biomarkers 
in the urine of cancer patients using SELDI-TOF mass 
spectrometry. We observed a downregulation of fragments 
of CTSC, argin, ARSA and GFAP all of which may play a 
role muscle wasting. Further investigation of specific assays 
monitoring expression levels in our proposed biomarkers 
would help translate our findings into the clinical setting. 
Investigations using a larger cohort would also confirm their 
validity.
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